Agostino Ingraldi, MD
Interventional Cardiology · Lafayette, LANPI 1427254432
Payments from drug & device makers
Across 837 payments — averaging $376.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$127K
- Johnson & Johnson$69K
- Lilly USA, LLC$64K
- Amgen$27K
- Esperion Therapeutics, Inc.$14K
- Abiomed$6K
- plus $8K from 39 others
What the payments were for
- Consulting fees$6,9252%
- Speaking & faculty fees$260,55483%
- Travel & lodging$30,31610%
- Food & beverage$17,3145%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$185,480
- XARELTO$66,621
- Repatha$26,490
- NEXLIZET$13,873
- NEXLETOL$13,873
- Impella$4,585
- FlowTriever$280
- ClotTriever$280
- ENDURANT IIS$195
- FLOWTRIEVER CATHETER, S$189
- CT THROMBECTOMY SYSTEM KIT$189
- CardioMEMS HF System$174
- Valiant Captivia$155
- Venclose Maven Catheter$152
- Sublime 014 Rx PTA Balloon Dilatation Catheter$145
- Sublime Radial Access 018 RX PTA Dilatation Catheter$145
- Sublime Radial Access Guide Sheath$145
- Pounce Thrombectomy System$145
- Pounce Venous Thrombectomy System$145
- PuraPly$125
How this compares
$315,113 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,114 | $912,573 |
| XareltoRivaroxaban | 730 | $620,252 |
| Repatha SureclickEvolocumab | 524 | $376,277 |
| EntrestoSacubitril/Valsartan | 233 | $208,713 |
| JardianceEmpagliflozin | 107 | $110,714 |
| Rosuvastatin Calcium | 4,231 | $54,574 |
| VascepaIcosapent Ethyl | 102 | $53,947 |
| Praluent PenAlirocumab | 80 | $52,691 |
| NexlizetBempedoic Acid/Ezetimibe | 75 | $38,726 |
| Ezetimibe | 1,913 | $33,370 |
| Metoprolol Succinate | 1,596 | $19,947 |
| Atorvastatin Calcium | 1,953 | $18,807 |
| NexletolBempedoic Acid | 46 | $18,738 |
| Repatha SyringeEvolocumab | 23 | $18,230 |
| LivaloPitavastatin Calcium | 23 | $16,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $716 | $912,5731,114 claims |
| Johnson & JohnsonXarelto | $68,932 | $620,252730 claims |
| NovartisEntresto | $1,375 | $208,713233 claims |
| Boehringer IngelheimJardiance, Pradaxa | $126,928 | $113,766122 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $14,311 | $57,463121 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $298 | $16,16223 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $151 | $9,85232 claims |
| AstraZenecaBrilinta | $264 | $9,49112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Lafayette
- Ankur LodhaLafayette$945K
- Louis SalvaggioLafayette$214K
- Eric ThomasseeLafayette$149K
- Amit AminLafayette$82K
- Raghotham PatlolaLafayette$76K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
- Stephen RameeNew Orleans$1.5M
- Denzil MoraesBaton Rouge$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.